|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A01N 63/00 | |
| A61K 48/00 | |||
| A61K 38/19 | |||
| A61K 31/4412 |
| (11) | Number of the document | 3409119 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18166620.7 |
| Date of filing the European patent application | 2010-09-14 | |
| (97) | Date of publication of the European application | 2018-12-05 |
| (45) | Date of publication and mention of the grant of the patent | 2020-08-12 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 242238 P | 2009-09-14 | US | |
| 244250 P | 2009-09-21 | US |
| (72) |
KIRN, David, US
BREITBACH, Caroline, US
|
| (73) |
SillaJen Biotherapeutics, Inc.,
450 Sansome Street, Suite 650, San Francisco, CA 94111,
US
|
| (54) | ONCOLYTIC VACCINIA VIRUS COMBINATION CANCER THERAPY |
| ONCOLYTIC VACCINIA VIRUS COMBINATION CANCER THERAPY |